TLR2 and metabolic syndrome: Specifically, we posit that reduction of Oscillibacter (and potentially other bacterial producers of Tlr2/5 ligands) levels and the consequent decrease and/or reprogramming of metabolically harmful IR-ATMs represents one of the main mechanisms of TXN therapeutic action in MetS (Fig. 6).